SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Bethany White, Annie Madden, Maria Prins, Margaret Hellard, Handan Wand, Gregory J. Dore, Kimberly Page, Lisa Maher, Assessing the feasibility of hepatitis C virus vaccine trials: Results from the Hepatitis C Incidence and Transmission Study-community (HITS-c) vaccine preparedness study, Vaccine, 2014, 32, 42, 5460

    CrossRef

  2. 2
    George V. Papatheodoridis, Emmanuel Tsochatzis, Svenja Hardtke, Heiner Wedemeyer, Barriers to care and treatment for patients with chronic viral hepatitis in Europe: a systematic review, Liver International, 2014, 34, 8
  3. 3
    Jason Grebely, Gregory J. Dore, Can hepatitis C virus infection be eradicated in people who inject drugs?, Antiviral Research, 2014, 104, 62

    CrossRef

  4. 4
    Francesco Negro, Curbing hepatitis C virus spread in Egypt, The Lancet Global Health, 2014, 2, 9, e495

    CrossRef

  5. 5
    Romulus Breban, Naglaa Arafa, Sandrine Leroy, Aya Mostafa, Iman Bakr, Laura Tondeur, Mohamed Abdel-Hamid, Wahid Doss, Gamal Esmat, Mostafa K Mohamed, Arnaud Fontanet, Effect of preventive and curative interventions on hepatitis C virus transmission in Egypt (ANRS 1211): a modelling study, The Lancet Global Health, 2014, 2, 9, e541

    CrossRef

  6. 6
    Margaret Hellard, Joseph S. Doyle, Rachel Sacks-Davis, Alexander J. Thompson, Emma McBryde, Eradication of hepatitis C infection: The importance of targeting people who inject drugs, Hepatology, 2014, 59, 2
  7. 7
    Harriet L. Mills, Samuel Johnson, Matthew Hickman, Nick S. Jones, Caroline Colijn, Errors in reported degrees and respondent driven sampling: Implications for bias, Drug and Alcohol Dependence, 2014, 142, 120

    CrossRef

  8. 8
    Natasha K. Martin, Peter Vickerman, David Goldberg, Matthew Hickman, HCV treatment as prevention in prison: Key issues, Hepatology, 2014, 60, 3
  9. 9
    N. Panneer, E. Lontok, B. M. Branson, C.-G. Teo, C. Dan, M. Parker, J. D. Stekler, A. DeMaria, V. Miller, HIV and Hepatitis C Virus Infection in the United States: Whom and How to Test, Clinical Infectious Diseases, 2014, 59, 6, 875

    CrossRef

  10. 10
    Margaret E Hellard, Joseph S Doyle, Interferon-free hepatitis C treatment: one pill to fit all?, The Lancet, 2014, 383, 9916, 491

    CrossRef

  11. 11
    Natasha K. Martin, Angela Devine, Jeffrey W. Eaton, Alec Miners, Timothy B. Hallett, Graham R. Foster, Gregory J. Dore, Philippa J. Easterbrook, Rosa Legood, Peter Vickerman, Modeling the impact of early antiretroviral therapy for adults coinfected with HIV and hepatitis B or C in South Africa, AIDS, 2014, 28, S35

    CrossRef

  12. 12
    Hamish Innes, David Goldberg, Geoffrey Dusheiko, Peter Hayes, Peter R. Mills, John F. Dillon, Esther Aspinall, Stephen T. Barclay, Sharon J. Hutchinson, Patient-important benefits of clearing the hepatitis C virus through treatment: A simulation model, Journal of Hepatology, 2014, 60, 6, 1118

    CrossRef

  13. 13
    Philip Bruggmann, Jason Grebely, Prevention, treatment and care of hepatitis C virus infection among people who inject drugs, International Journal of Drug Policy, 2014,

    CrossRef

  14. 14
    Michael H. Levy, Sarah Larney, The ethics of hepatitis C “treatment as prevention” among prisoners, Hepatology, 2014, 60, 3
  15. 15
    John W. Ward, The Role of Public Health in an Era of All-Oral Therapy for Hepatitis C Infection, Current Hepatitis Reports, 2013, 12, 4, 220

    CrossRef

  16. 16
    Philip Bruggmann, Treatment as prevention: The breaking of taboos is required in the fight against hepatitis C among people who inject drugs, Hepatology, 2013, 58, 5